Lausanne, Switzerland, November 21, 2017 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will host a Key Opinion Leader (KOL) luncheon meeting on the importance of Tau as a target in Alzheimer's disease and other neurodegenerative diseases on December 1, 2017 from 12.00pm - 1.45pm ET at the St. Regis Hotel, 2 E. 55th Street in New York, NY.
The meeting will feature presentations by KOLs Khalid Iqbal, PhD (New York State Institute for Basic Research in Developmental Disabilities) and Michael Rafii, MD, PhD (UC San Diego). They will discuss the mechanism and importance of Tau in the pathology and treatment of Alzheimer's and other neurodegenerative diseases, the role of diagnostics in Alzheimer's and a review of research on Tau and Amyloid in people with Down syndrome.
AC Immune's management team will provide an overview of the Company's robust and diverse pipeline of nine therapeutic and three diagnostic product candidates. The Company has a clear strategy to invest and build value in each of the three pillars of its business -- Alzheimer's disease, other significant neurodegenerative diseases and neuro-orphan indications, and diagnostics.
A Q&A session with the featured KOLs and the management will follow the presentations.
This event is intended for institutional investors, sell-side analysts, and pharmaceutical business development professionals only. Please RSVP in advance if you plan to attend, as space is limited.
A live webcast and replay of the event will be available on the Investor Page of AC Immune's website.
Khalid Iqbal, PhD
Dr. Khalid Iqbal is Professor and Chairman, Department of Neurochemistry at the New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York. He received his PhD in Biochemistry in 1969 from the University of Edinburgh, Edinburgh, U.K. Dr. Iqbal was the first to bulk-isolate neurofibrillary tangles and decipher their protein composition from autopsied brains of cases with Alzheimer's disease in 1974. These pioneering studies led him to the discoveries of Tau protein as the major protein subunit of the tangles and its abnormal hyperphosphorylation in Alzheimer's disease in 1986. Dr. Iqbal has received numerous awards, including the Potamkin Prize for Alzheimer Disease Research from the American Academy of Neurology, the Zenith Award from the Alzheimer's Association, U.S.A and Honorary Doctor of Science degree from the City University of New York College of Staten Island. In 2007, Alzheimer's Association, USA, established a Khalid Iqbal Life Time Achievement Award for Alzheimer's Disease Research, which is given out annually at the International Conference on Alzheimer's Disease (AAIC) to a senior established Alzheimer disease researcher. Dr. Iqbal has authored over 400 scientific papers in prestigious American and international scientific journals and edited seven books on research advances in Alzheimer's disease and related neurodegenerative disorders. He currently serves on editorial boards of several journals and scientific advisory committees of biotechnology companies.
Michael Rafii, MD, PhD
Dr. Michael Rafii, MD, PhD, is a board-certified neurologist and Associate Professor of Neuroscience and Founding Director of the Adult Down Syndrome Clinic at UC San Diego. Dr. Rafii leads multiple research programs studying the link between Alzheimer's disease and Down syndrome. He completed a fellowship in dementia and cognitive disorders at UC San Diego. He completed his neurology residency at the Johns Hopkins Hospital, where he was chief resident. He received his medical and doctorate degrees from Brown University School of Medicine and conducted neurogenetics research at Harvard Medical School. Dr. Rafii serves on the National Task Group on Intellectual Disabilities and Dementia Practices of the American Academy of Developmental Medicine and is co-editor of the textbook Common Pathogenic Mechanisms between Down Syndrome and Alzheimer's Disease: Steps toward Therapy. Dr. Rafii received the Star Award from the Down Syndrome Association of San Diego for his efforts to improve the lives of people with this condition. He is also Clinical Director of the Alzheimer's Therapeutic Research Institute (ATRI) at the Keck School of Medicine of USC.
About AC Immune
AC Immune is a clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases with four product candidates in clinical trials. The Company designs, discovers and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins. AC Immune's two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline features nine therapeutic and three diagnostic product candidates. The most advanced of these is crenezumab, an anti-Abeta antibody in Phase 3 clinical studies for AD that is being conducted by the collaboration partner Genentech. Other collaborations include Biogen, Janssen Pharmaceuticals, Nestlé Institute of Health Sciences, Piramal Imaging and Essex Bio-Technology.
Forward Looking Statements
This press release contains statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions "Item 3. Key Information-Risk Factors" and "Item 5. Operating and Financial Review and Prospects" in AC Immune's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
For further information, please contact:
| In Europe |
AC Immune Corporate Communications
Phone: +41 21 345 91 34
| In the US |
AC Immune Investor Relations
Phone: +1 970 987 26 54
| Nick Miles /Toomas Kull |
Cabinet Privé de Conseils s.a.
Phone: +41 22 552 46 46
| Ted Agne |
The Communications Strategy Group Inc.
Phone: +1 781 631 3117